Clinical Partnerships Position LIFT BioSciences as a partner for early clinical collaboration with academic or pharma entities, leveraging their allogeneic IMANs platform and ongoing Ireland/Europe clinical development efforts to accelerate trials and share manufacturing capabilities.

Manufacturing Synergy Target contract manufacturing organizations and GMP providers to offer LIFT’s iPSC-derived alpha neutrophil production capabilities, highlighting their scalable manufacturing platform and existing Minaris collaboration for European trial supply.

Pipeline Enablement Leverage the company’s differentiated solid-tumor focus to identify co-development or licensing opportunities with mid-to-large oncology players seeking antigen-independent cell therapies to overcome tumor microenvironment resistance.

Funding Continuity Engage with potential investors and strategic partners emphasizing recent Series A funding and expanding leadership, underscoring the trajectory to de-risk clinical programs and expedite first-in-human studies.

Academic Collaborations Explore formal research partnerships with universities and research centers (e.g., University of Galway) for clinical trial execution, translational studies, and access to patient cohorts in Ireland and Europe.